TGF-β1 signalling, connecting aberrant inflammation and colorectal tumorigenesis

Current Pharmaceutical Design

Volumn 18, Issue 26, 2012, Pages 3874-3888

  Skeen, Victoria R ^a   Paterson, Ian ^b   Paraskeva, Christos ^a   Williams, Ann C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Inflammatory bowel disease and colorectal cancer; TGF 1

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LY 2109761; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; S6 KINASE; SMAD PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRABEDERSEN; TRANSCRIPTION FACTOR GLI2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN;

5' UNTRANSLATED REGION; ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOSTASIS; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GLIOMA; HEMATOPOIESIS; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INTESTINE EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UBIQUITINATION; ULCERATIVE COLITIS; WNT SIGNALING PATHWAY;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864531145     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802083734     Document Type: Review

References (184)

1. Ikushima, H, Miyazono, K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010b; 10(6): 415-24.
2. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110(4): 975-84.
3. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14(27): 4280-8.
4. Massagué, J. TGF-beta in cancer. Cell 2008; 134(2): 215-30.
5. Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993; 68(1): 137-9.
6. Barnard JA, Warwick GJ, Gold LI. Localization of transforming growth factor beta isoforms in the normal murine small intestine and colon. Gastroenterology 1993; 105(1): 67-73.
7. Fujii D, Brissenden J, Derynck R, Francke U. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 1986; 12(3): 281-8.
8. Barton D, Foellmer B, Du J, Tamm J, Derynck R, Francke U. Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family. Oncogene Res 1988; 3(4): 323-31.
9. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282(1): C172-82.
10. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 1981; 78(9): 5339-43.
11. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985; 82(1): 119-23.
12. Roberts AB, Wakefield LM. The two faces of transforming growth factor-beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100(15): 8621-3.
13. Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC. Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci USA 1986; 83(8): 2438-42.
14. McMahon JB, Richards WL, del Campo AA, Song MK, Thorgeirsson SS. Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res 1986; 46(9): 4665-71.
15. Shipley GD, Pittelkow MR, Wille JJ, Jr Scott RE, Moses HL. Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serumfree medium. Cancer Res 1986; 46(4_Part_2): 2068-71.
16. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21(2): 166-76.
17. Kim SJ, Glick A, Sporn MB, Roberts AB. Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J Biol Chem 1989; 264(1): 402-8.
18. Kim SJ, Angel P, Lafyatis R, et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990; 10(4): 1492-7.
19. Kim SJ, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB. Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989; 264(32): 19373-8.
20. Kim S, Lee H, Robbins PD, Busam K, Sporn MB, Roberts AB. Regulation of transforming growth factor beta1 gene expression by the product of the Retinoblastoma-susceptibility gene. Proc Natl Acad Sci USA 1991; 88(8): 3052-6.
21. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci USA 1996; 93(21): 11831-6.
22. Lee KY, Ito K, Hayashi R, Jazrawi EPI, Barnes PJ, Adcock IM. NF-kappa B and activator protein 1 response elements and the role of histone modifications in IL-1-beta-induced TGF-beta 1 gene transcription. J Immunol 2006; 176(1): 603-15.
23. Parrelli JM, Meisler N, Cutroneo KR. Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter. Int J Biochem Cell Biol 1998; 30(5): 623-7.
24. Qi W, Gao S, Wang Z. Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J 2008; 416: 453-62.
25. Gault N, Vozenin-Brotons MC, Calenda A, Lefaix JL, Martin MT. Promoter sequences involved in transforming growth factor beta 1 gene induction in HaCaT keratinocytes after gamma irradiation. Radiat Res 2002; 157(3): 249-55.
26. Liu G, Ding W, Liu X, Mulder KM. c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. Mol Carcinog 2006; 45(8): 582-93.
27. Salbert G, Fanjul A, Piedrafita FJ, et al. Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol Endocrinol 1993; 7(10): 1347-56.
28. Lee SJ, Yang JW, Cho IJ, Kim WD, Cho MK, Lee CH, Kim SG. The gep oncogenes, Galpha12 and Galpha13, upregulate the transforming growth factor-beta1 gene. Oncogene 2009; 28(9): 1230-40.
29. Worzfeld T, Wettschureck N, Offermanns S. G12/G13-mediated signalling in mammalian physiology and disease. Trends Pharmacol Sci 2008; 29(11): 582-9.
30. Shull S, Meisler N, Absher M, Phan S, Cutroneo K. Glucocorticoid-induced down regulation of transforming growth factor-beta 1 in adult rat lung fibroblasts. Lung 1995; 173(2): 71-8.
31. Wen FQ, Kohyama T, Skold CM,. Glucocorticoids modulate TGFbeta production by human fetal lung fibroblasts. Inflammation 2003; 27(1): 9-19.
32. Muraoka RS, Bushdid PB, Brantley DM, Yull FE, Kerr LD. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev Biol 2000; 225(2): 322-38.
33. Phillips AO, Topley N, Steadman R, Morrisey K, Williams JD. Induction of TGF-beta 1 synthesis in D-glucose primed human proximal tubular cells by IL-1 beta and TNF alpha. Kidney Int 1996; 50(5): 1546-54.
34. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000; 165(4): 2271-7.
35. Warshamana GS, Corti M, Brody AR. TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-alpha induces TGF-beta(1). Exp Mol Pathol 2001; 71(1): 13-33.
36. Southern SL, Collard TJ, Urban BC, et al. BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis. Oncogene 2011; Epub ahead of print.
37. Pereira SG, Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol 2008; 40(8): 1425-30.
38. Clemo NK, Collard TJ, Southern SL, et al. BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis 2008; 29(4): 849-57.
39. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316(6030): 701-5.
40. Janssens K, Gershoni-Baruch R, Guanabens N, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta1 cause Camurati-Engelmann disease. Nat Genet 2000; 26(3): 273-27.
41. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993; 73(7): 1435-44.
42. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell 1991; 67(4): 797-805.
43. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 2002; 277(1): 823-29.
44. Dong M, How T, Kirkbride KC, et al. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007; 117(1): 206-17.
45. Bandyopadhyay A, Zhu Y, Malik SN, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002; 21(22): 3541-51.
46. Yan Z, Deng X, Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J Biol Chem 2001; 276(2): 1555-63.
47. Gatza CE, Holtzhausen A, Kirkbride KC, et al. Type III TGF-β receptor enhances colon cancer cell migration and anchorageindependent growth. Neoplasia 2011; 13(8): 758-70.
48. Wrighton KH, Feng XH. To (TGF)beta or not to (TGF)beta: Finetuning of Smad signaling via post-translational modifications. Cell Signal 2008; 20(9): 1579-91.
49. Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGFbeta / Smad signaling by oncogenic Ras. Genes Dev 1999; 13(7): 804-16.
50. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001; 98(3): 974-9.
51. Inoue Y, Itoh Y, Abe K, et al. Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 2007; 26(4): 500-8.
52. Simonsson M, Kanduri M, Gronroos E, Heldin CH, Ericsson J. The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. J Biol Chem 2006; 281(52): 39870-80.
53. Tu AW, Luo K. Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. J Biol Chem 2007; 282(29): 21187-96.
54. Mulder KM, Levine AE, Hernandez X, et al. Modulation of C-myc by transforming growth factor-beta in human colon carcinoma cells. Biochem Biophys Res Commun 1988; 150(2): 711-6.
55. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X. Transforming growth factor-beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92(12): 5545-9.
56. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8(1): 9-22.
57. Hannon GJ, Beach D. p15INK4B is a potential effector of TGFbeta-induced cell cycle arrest. Nature 1994; 371(6494): 257-61.
58. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998; 95(6): 779-91.
59. Runyan CE, Hayashida T, Hubchak S, Curley JF, Schnaper HW. Role of SARA (SMAD anchor for receptor activation) in maintenance of epithelial cell phenotype. J Biol Chem 2009; 284(37): 25181-9.
60. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41(4): 263-2.
61. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signalling, Cell 1997; 89(7): 1165-73.
62. Valdimarsdottir G, Goumans MJ, Itoh F, Itoh S, Heldin CH, ten Dijke P. Smad7 and protein phosphatase 1alpha are critical determinants in the duration of TGF-beta/ALK1 signaling in endothelial cells. BMC Cell Biol 2006; 29: 7: 16.
63. Shi W, Sun C, He B, et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGF-beta type I receptor. J Cell Biol 2004; 164(2): 291-300.
64. Hanyu, A, Ishidou, Y, Ebisawa, T, Shimanuki, T, Imamura, T, Miyazono, K. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J Cell Biol 2001; 155(6): 1017-27.
65. Zhang S, Fei T, Zhang L, et al. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 2007; 27(12): 4488-99.
66. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19(1): 128-39.
67. Petritsch C, Beug H, Balmain A, Oft M. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev 2000; 14(24): 3093-101.
68. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247-69.
69. Mucsi I, Skorecki KL, Goldberg HJ. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta 1 on gene expression. J Biol Chem 1996; 271(28): 16567-72.
70. Wilkes MC, Murphy SJ, Garamszegi N, Leof EB. Cell-typespecific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 2003; 23(23): 8878-89.
71. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13(3): 902-14.
72. Imamichi Y, Waidmann O, Hein R, Eleftheriou P, Giehl K, Menke A. TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem 2005; 386(3): 225-36.
73. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005; 307(5715): 1603-9.
74. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011; 23(6): 951-62.
75. Bhowmick, NA, Ghiassi, M, Bakin, A, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12(1): 27-36.
76. Liu P, Cheng H, Roberts TM, Zhao JJ () Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8(8): 627-44.
77. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2(7): 489-501.
78. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instabilityhigh sporadic colorectal cancers. Cancer Res 2004; 64(9): 3014-21.
79. Zhou XP, Loukola A, Salovaara R, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002; 161(2): 439-47.
80. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer-mutations in a signalling pathway. Nature 2005; 436(7052): 792-2.
81. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275(47): 36803-10.
82. Chow JY, Cabral JA, Chang J, Carethers JM. TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol Ther 2008; 7(10): 1694-9.
83. Lamouille S, Derynck R Cell size and invasion in TGF-beta induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007; 178(3): 437-51.
84. Muraoka-Cook RS, Shin I, Yi JY, et al. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelia cells and accelerates tumor progression. Oncogene 2006; 25(24): 3408-23.
85. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Aktdependent regulation of FKHRL1. Mol Biol Cell 2001; 12(11): 3328-39.
86. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 2005; 280(11): 10870-6.
87. Wilkes MC, Mitchell H, Penheiter SG, et al. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005; 65(22): 10431-40.
88. Mulder KM, Morris SL. Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem 1992; 267(8): 5029-31.
89. Yan Z, Winawer S, Friedman E. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994; 269(18): 13231-7.
90. Frey RS, Mulder KM. TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. Cancer Lett 1997; 117(1): 41-50.
91. Lee MK, Pardoux C, Hall MC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007; 26(17): 3957-67.
92. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signalregulated kinase 2 activation. Cancer Res 2001; 61(10): 4222-8.
93. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9(8): 537-49.
94. Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinaseindependent manner. Nat Cell Biol 2008; 10(10): 1199-207.
95. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGFbeta. Mol Cell 2008; 31(6): 918-24.
96. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGFbeta signal transduction. Science 1995; 270(5244): 2008-11.
97. Dempsey CE, Sakurai H, Sugita T, Guesdon F. Alternative splicing and gene structure of the transforming growth factor beta-activated kinase 1. Biochim Biophys Acta 2000; 1517(1): 46-52.
98. Edlund S, Bu S, Schuster N, et al. Transforming growth factorbeta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 2003; 14(2): 529-44.
99. Zhang S, Ekman M, Thakur N, et al. TGFbeta1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle 2006; 5(23): 2787-95.
100. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-betamediated transcription. J Biol Chem 1999; 274(52): 37413-20.
101. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999; 18(5): 1345-56.
102. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25(5): 1375-82.
103. -/-colon carcinoma. Science 1997; 275: 1784-7.
104. Morin P J. Sparks AB, Korinek V, et al. Activation of-catenin-Tcf signaling in colon cancer by mutations in-catenin or APC. Science 1997; 275: 1787-90
105. Simons BD, Clevers H Stem cell self-renewal in intestinal crypt. Exp Cell Res 2011; 317(19): 2719-24.
106. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25(57): 7531-7.
107. Guo X, Wang XF. Signaling cross-talk between TGF β/BMP and other pathways. Cell Research 2009; 19: 71-88.
108. Labbé E, Lock L, Letamendia A, et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 2007; 67: 75-84.
109. Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion. Cell Cycle 2010; 9: 2363-74.
110. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008; 22(18): 2454-72. Review
111. Ng JM, Curran T. The Hedgehog's tail: developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.
112. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res 2011; 71(17): 5606-10.
113. Dennler S, André J, Alexaki I, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007; 67: 6981-6.
114. Dennler S, André J, Verrecchia F, Mauviel A. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J Biol Chem 2009; 284: 31523-31.
115. Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis 2008; 29: 480-90.
116. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development 2011; 138: 3593-612.
117. Miyamoto S, Rosenberg DW. Role of Notch signalling in colon homeostasis and carcinogenesis. Cancer Sci 2011; 102: 1938-42.
118. Chen ZY, Rex S, Tseng CC. Krüppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr 2004; 134(4): 792-8.
119. Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW. Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res 2007; 67: 7147-54.
120. Sjölund J, Boström AK, Lindgren D, et al. The notch and TGF-β signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One 2011; 6: e23057. Epub 2011 Aug 3.
121. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359(6397): 693-699.
122. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18: 1280-91.
123. Gorelik L, Flavell RA. Abrogation of TGF beta signalling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-81.
124. Li MO, Flavell RA. TGF-β: A master regulator of all T cell trades. Cell 2008; 134: 392-404.
125. Maruyama T, Konkel JE, Zamarron BF, Chen W. The molecular mechanisms of Foxp3 gene regulation. Semin Immunol 2011; Epub ahead of print.
126. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441(7090): 235-8.
127. Marek A, Brodzicki J, Liberek A, Korzon M. TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions-a new diagnostic and prognostic marker? Med Sci Monit 2002; 8: RA145-51
128. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGFbeta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9
129. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 2008; 1 (Suppl 1): S50-53.
130. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118(6): 671-4.
131. Hafez MM, Hsu S, Yan Z, Winawer S, Friedman E. Two roles for transforming growth factor beta 1 in colon enterocytic cell differentiation. Cell Growth Differ 1992; 3(11): 753-62.
132. Kurokowa M, Lynch K, Podolsky DK. Effects of growth factors on an intestinal epithelial cell line: transforming growth factor beta inhibits proliferation and stimulates differentiation. Biochem Biophys Res Commun 1987; 142(3): 775-82.
133. Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta-induced apoptosis. Nat Cell Biol 2004; 6(4): 366-72.
134. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGFbeta induces apoptosis through Smad-mediated expression of DAPkinase. Nat Cell Biol 2002; 4(1): 51-8.
135. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001; 3(8): 708-14.
136. Wang J, Yang L, Yang J, et al. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 2008; 68(9): 3152-60.
137. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127(6 Pt 2): 2021-36.
138. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999; 112 (Pt 24)4557-68.
139. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19(2): 156-72.
140. Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006; 66(4): 2202-9.
141. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 2002; 115(Pt 6): 1189-202.
142. Janda E, Lehmann K, Killisch I, et al. Ras and TGF-beta cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156(2): 299-314.
143. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGFbeta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10(19): 2462-77.
144. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23(9): 2078-93.
145. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol 2007; 13(22): 3056-62.
146. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121(6): 1845-54.
147. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009; 19(1): 116-27.
148. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21(7): 1743-53.
149. Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 2004; 279(16): 16388-93.
150. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91(5): 964-71.
151. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factorbeta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995; 89(1): 45-8.
152. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004; 64(13): 4405-10.
153. Sugano Y, Matsuzaki K, Tahashi Y, et al. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 2003; 22(15): 2309-21.
154. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37(1): 19-29.
155. Xiong B, Gong LL, Zhang F, Hu MB, Yuan HY. TGF beta1 expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol 2002; 8(3): 496-8.
156. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factorbeta in fibroblastic and epithelial cells. J Biol Chem 1994; 269(9): 6271-4.
157. Lin SW, Lee MT, Ke FC, et al. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 2000; 18(6): 493-9.
158. Safina A, Vandette E, Bakin AV. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 2006; 26(17): 2407-22.
159. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and-2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 1999; 10(2): 407-16.
160. Shimizu S, Nishikawa Y, Kuroda K, et al. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996; 56(14): 3366-70.
161. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31(6): 220-7.
162. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the Type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268(5215): 1336-8.
163. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor-beta receptor Type II in microsatellite stable colon cancers. Cancer Res 1999; 59(2): 320-4.
164. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344(16): 1196-206.
165. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003; 306(4): 799-804.
166. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999; 18(20): 3098-103.
167. Xu WQ, Jiang XC, Zheng L, Yu YY, Tang JM. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma. Exp Mol Pathol 2007; 82(3): 284-91.
168. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Ann Rev Genomics Hum Genet 2002; 3(1): 101-28.
169. Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett 1998; 122(1-2): 157-63.
170. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57(13): 2578-80.
171. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta-1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995; 4(5): 549-54.
172. Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomarkers Prev 1998; 7(6): 497-504.
173. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110(2): 375-82.
174. Manning AM, Williams AC, Game SM, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 1991; 6(8): 1471-6.
175. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. TGF-beta signalling in colon carcinogenesis. Cancer Lett 2011; Oct 7. [Epub ahead of print]
176. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-β in cancer. J Pathol 2011; 223(2): 205-18.
177. Santibanez JF, Quintanilla M, Bernabeu C. TGF-β/ TGF-β receptor system and its role in physiological and pathological conditions. Clinical science 2011; 121: 233-51.
178. Bandyopadhyay A, Zhu Y, Malik SN, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002; 21(22): 3541-51.
179. Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009; 277(1): 114-20.
180. Jaschinski F, Rothhammer T, Jachimczak P, Seitz C, Schneider A, Schlingensiepen KH. The antisense oligonucleotide Trabedersen (AP 12009) for the targeted inhibition of TGF-β2. Curr Pharm Biotechnol 2011 May 27. [Epub ahead of print]
181. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-β1 and Smad7 in the regulation of IBD. Mucosal Immunology 2008; 1 (1): S50-S53.
182. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006; 131(6): 1786-98.
183. Sharp A, Crabb SJ, Johnson PW, et al. Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions. J Pharmacol Exp Ther 2009; 331(2): 680-9.
184. Sharp A, Cutress RI, Johnson PW, Packham G, Townsend PA. Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth. FEBS Lett, 2009; 583(21): 3405-11.